北京嘉宝仁和医疗科技有限公司（以下简称嘉宝仁和），国家级高新技术企业，成立于2011年6月，在北京大兴生物医药产业基地拥有6000平方米的研发中心、GMP生产车间和培训基地，拥有多项发明专利。
嘉宝仁和是辅助生殖领域利用新一代测序提供遗传学解决方案的先行者和领导者，作为细分行业龙头，目前嘉宝仁和的胚胎植入前遗传学筛查(PGS)/诊断(PGD)检测技术、测序平台和分析系统等已经覆盖了中国大陆地区70%以上的经国家批准开展PGD的生殖医学中心。其开创性的染色体易位携带者PGD技术，单基因病PGD技术和男性不育基因检测技术在国际上都处于领先地位。同时，作为PGS创新医疗器械的企业之一，嘉宝仁和不但为标准的制定提供了有力的数据支撑，自身也参与了多项行业内标准的制定工作。
目前，嘉宝仁和已经建成拥有一个医学检验实验室、一个研究所、一个生产基地的保障网络，以及覆盖全国市场的临床检验支持团队和一线营销专业团队。
在推广和提供领先的检测技术和产品服务同时，公司研发部门保持了充足的技术储备，为公司的持续发展和核心竞争力建设打下了坚实的基础。
Jabrehoo is the pioneer and leader in providing Next Generation Sequencing based genetics solutions for the assisted reproductive centers in China.
As the leader of market segment on Assisted Reproduction Genetic Testing, our product line covers equipment, consumables, diagnostic reagents and medical bioinformatics platform, as well as genetic counseling. Over 70% of state authorized PGD IVF centers are using Jabrehoo’s Next Generation Sequencing based PGS/PGD solution.
Jabrehoo’s cutting edge technologies include, but not limited to: MicroSeqTM Balanced Translocation Carrier PGD, S-PGDTM Robertsonian Translocation Carrier PGD, S-PGDTM for Monogenic Disorders and global leading Male infertility DNA testing.
Simultaneously, as a medical company, Jabrehoo’s PGS kit has received the CMDE’s (CENTER FOR MEDICAL DEVICE EVALUATION, CFDA, CHINA) special approval of innovative medical device/diagnostic kit. Out accumulated data and experience has given a solid support for the National PGS standard establishment led by NIFDC. In addition, Jabrehoo herself is participating several other PGS/PGD standard/good practice led by government and CSRM.
北京嘉宝仁和医疗科技有限公司（以下简称嘉宝仁和），国家级高新技术企业，成立于2011年6月，在北京大兴生物医药产业基地拥有6000平方米的研发中心、GMP生产车间和培训基地，拥有多项发明专利。
嘉宝仁和是辅助生殖领域利用新一代测序提供遗传学解决方案的先行者和领导者，作为细分行业龙头，目前嘉宝仁和的胚胎植入前遗传学筛查(PGS)/诊断(PGD)检测技术、测序平台和分析系统等已经覆盖了中国大陆地区70%以上的经国家批准开展PGD的生殖医学中心。其开创性的染色体易位携带者PGD技术，单基因病PGD技术和男性不育基因检测技术在国际上都处于领先地位。同时，作为PGS创新医疗器械的企业之一，嘉宝仁和不但为标准的制定提供了有力的数据支撑，自身也参与了多项行业内标准的制定工作。
目前，嘉宝仁和已经建成拥有一个医学检验实验室、一个研究所、一个生产基地的保障网络，以及覆盖全国市场的临床检验支持团队和一线营销专业团队。
在推广和提供领先的检测技术和产品服务同时，公司研发部门保持了充足的技术储备，为公司的持续发展和核心竞争力建设打下了坚实的基础。
Jabrehoo is the pioneer and leader in providing Next Generation Sequencing based genetics solutions for the assisted reproductive centers in China.
As the leader of market segment on Assisted Reproduction Genetic Testing, our product line covers equipment, consumables, diagnostic reagents and medical bioinformatics platform, as well as genetic counseling. Over 70% of state authorized PGD IVF centers are using Jabrehoo’s Next Generation Sequencing based PGS/PGD solution.
Jabrehoo’s cutting edge technologies include, but not limited to: MicroSeqTM Balanced Translocation Carrier PGD, S-PGDTM Robertsonian Translocation Carrier PGD, S-PGDTM for Monogenic Disorders and global leading Male infertility DNA testing.
Simultaneously, as a medical company, Jabrehoo’s PGS kit has received the CMDE’s (CENTER FOR MEDICAL DEVICE EVALUATION, CFDA, CHINA) special approval of innovative medical device/diagnostic kit. Out accumulated data and experience has given a solid support for the National PGS standard establishment led by NIFDC. In addition, Jabrehoo herself is participating several other PGS/PGD standard/good practice led by government and CSRM.
中国 - 北京市/北京市 合资 100-499人
社区
直聘
中国 - 北京市/北京市
中国 - 淮北市/安徽省 
